Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer.

No abstract is available for this paper.

• Publication year

  1974

• Venue

  Clinical Immunology and Immunopathology

• Publication date

  1974-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0090-1229(74)90012-9PMID 4141659
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen

  1973cited by this paper
• In vivo and in vitro immunological cross‐reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis

  1973cited by this paper
• Protection against Experimental Allergic Encephalomyelitis

  1972cited by this paper
• Species specificity in response to tryptophan modified encephalitogen.

  1972cited by this paper
• Suppression of the Immune Response: Reversal of the Disease State with Antigen in Allergic Encephalomyelitis

  1972cited by this paper
• Allergic encephalomyelitis in monkeys induced by a peptide from the A1 protein.

  1972cited by this paper
• Biological activity of an encephalitogenic fragment in the monkey.

  1972cited by this paper
• Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

  1971cited by this paper
• Encephalitogenic activity in rabbits of the C‐terminal region of bovine basic myelin protein

  1971cited by this paper
• Basic encephalitogenic protein: A simplified purification on sulphoethyl‐sephadex

  1970cited by this paper
• Allergic encephalomyelitis: isolation and characterization of encephalitogenic peptides from the basic protein of bovine spinal cord.

  1969cited by this paper
• Protective action of the encephalitogen and other basic proteins in experimental allergic encephalomyelitis.

  1968cited by this paper
• Isolation and properties of an encephalitogenic protein from bovine, rabbit, and human central nervous system tissue.

  1968cited by this paper
• Experimental allergic encephalomyelitis and autoimmune disease.

  1966cited by this paper
• ENCEPHALITOGEN‐INDUCED INHIBITION OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS: PREVENTION, SUPPRESSION AND THERAPY *

  1965cited by this paper
• CHEMICAL STUDIES ON AN ENCEPHALITOGENIC PROTEIN FROM GUINEA PIG BRAIN

  1965cited by this paper
• IMMUNOCHEMICAL STUDIES ON BLOOD GROUPS

  1947cited by this paper
• ALLERGIC ENCEPHALOMYELITIS IN MONKEYS IN RESPONSE TO INJECTION OF NORMAL MONKEY NERVOUS TISSUE

  1946cited by this paper
• THE RAPID PRODUCTION OF ACUTE DISSEMINATED ENCEPHALOMYELITIS IN RHESUS MONKEYS BY INJECTION OF HETEROLOGOUS AND HOMOLOGOUS BRAIN TISSUE WITH ADJUVANTS

  1946cited by this paper

• Assessing the In Vitro Potential of Glatiramer Acetate (Copaxone®) as a Chemotherapeutic Candidate for the Treatment of Cryptococcus neoformans Infection

  2023cites this paper
• The Immune Response in Multiple Sclerosis.

  2021cites this paper
• The impact of translational research on the development of therapeutic agents for multiple sclerosis

  2021cites this paper
• Glatiramer Acetate: from Bench to Bed and Back.

  2019cites this paper
• The Evolving Mechanisms of Action of Glatiramer Acetate.

  2019cites this paper
• Experimental Autoimmune Encephalomyelitis (EAE) as Animal Models of Multiple Sclerosis (MS).

  2018cites this paper
• Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis

  2017cites this paper
• Process signatures in glatiramer acetate synthesis: structural and functional relationships

  2017cites this paper
• Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar

  2017cites this paper
• Experimental autoimmune encephalomyelitis from a tissue energy perspective

  2017cites this paper
• Two decades of glatiramer acetate: From initial discovery to the current development of generics.

  2017cites this paper
• Immunomodulation of Glatiramer Acetate in Multiple Sclerosis

  2016cites this paper
• Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis

  2016cites this paper
• Immunomodulatory effects of glatiramer acetate as they relate to stage-specific immune dysregulation in multiple sclerosis.

  2016cites this paper
• A Journey in Science: The Privilege of Exploring the Brain and the Immune System

  2016cites this paper
• 多発性硬化症における免疫病態とグラチラマー酢酸塩（コパキソン®皮下注20 mgシリンジ）の免疫調整作用

  2016cites this paper
• From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development.

  2014cites this paper
• The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.

  2014cites this paper
• Immune regulation of multiple sclerosis by CD8+ T cells

  2014cites this paper
• Glatiramer acetate and therapeutic peptide vaccines for multiple sclerosis

  2014cites this paper
• Immune regulation of multiple sclerosis by CD8+ T cells

  2014cites this paper
• Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

  2014cites this paper
• Analyzing the effects of laquinimod on innate and adaptive immunity in mice with experimental autoimmune encephalomyelitis

  2014cites this paper
• Animal models of human disease: inflammation.

  2014cites this paper
• Update on immunopathogenesis and immunotherapy in multiple sclerosis

  2013cites this paper
• HUMAN HERPESVIRUS-6 IN MULTIPLE SCLEROSIS: ASSAY DEVELOPMENT, IMMUNE RESPONSES AND HOST GENETICS

  2013influential citation
• From genetic associations to biological implications in multiple sclerosis

  2013cites this paper
• Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects.

  2012cites this paper
• Immunization with A91 peptide or copolymer‐1 reduces the production of nitric oxide and inducible nitric oxide synthase gene expression after spinal cord injury

  2012cites this paper
• Glatiramer acetate for treatment of relapsing–remitting multiple sclerosis

  2012cites this paper
• Glatiramer Acetate‐Specific Antibody Titres in Patients with Relapsing / Remitting Multiple Sclerosis and in Experimental Autoimmune Encephalomyelitis

  2011cites this paper
• Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)

  2011cites this paper
• Glatiramer Acetate in the Treatment of Multiple Sclerosis

  2011cites this paper
• Peptides and Polypeptides as Immunomodulators and Their Consequential Therapeutic Effect in Multiple Sclerosis and Other Autoimmune Diseases

  2011cites this paper
• Glatiramer Acetate in the Reduction of Relapse Frequency in Multiple sclerosis

  2011cites this paper
• Translational research in neurology and neuroscience 2010: multiple sclerosis.

  2010cites this paper
• Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update

  2010influential citation
• Translational research in neurology and neuroscience 2010-2011.

  2010cites this paper
• Are current disease‐modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?

  2010cites this paper
• Basic Protein as a Ligand for Integrin Structural Insight into the Function of Myelin

  2008cites this paper
• Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production

  2008cites this paper
• Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model.

  2008cites this paper
• Structural Insight into the Function of Myelin Basic Protein as a Ligand for Integrin αMβ21

  2008cites this paper
• Glatiramer acetate in multiple sclerosis: a review.

  2007cites this paper
• Glatiramer acetate: mechanisms of action in multiple sclerosis.

  2007cites this paper
• Glatiramer acetate: mechanisms of action in multiple sclerosis.

  2007cites this paper
• The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis

  2007cites this paper
• Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis.

  2006cites this paper
• How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis

  2006cites this paper
• Immunomodulatory Vaccines Against Autoimmune Diseases

  2006cites this paper
• Glatiramer acetate in the treatment of multiple sclerosis.

  2005cites this paper
• Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.

  2005cites this paper
• Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis.

  2005cites this paper
• Long-term follow up of glatiramer acetate compassionate use in Belgium.

  2005cites this paper
• Antigen-Specific Therapies in Multiple Sclerosis

  2005cites this paper
• Antigen-Specific Therapies in Multiple Sclerosis: Going Beyond Proteins and Peptides

  2005cites this paper
• Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate.

  2004cites this paper
• Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms.

  2004cites this paper
• Peptidic complex mixtures as therapeutic agents in CNS autoimmunity.

  2004cites this paper
• My world through science

  2004cites this paper
• Therapeutic vaccines in autoimmunity

  2004cites this paper
• Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis.

  2004cites this paper
• Immunomodulation by the copolymer glatiramer acetate

  2003cites this paper
• From Proteins and Protein Models to Their Use in Immunology and Immunotherapy

  2003cites this paper
• [Treatment of multiple sclerosis with glatiramer acetate. Current aspects of mechanisms of action, pharmacokinetics, adverse effect profile and clinical studies].

  2002cites this paper
• Glatiramer acetate.

  2002cites this paper
• Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.

  2002cites this paper
• Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.

  2002cites this paper
• Immuntherapie der multiplen Sklerose mit Glatiramerazetat (Copaxone®)

  2002cites this paper
• Behandlung der Multiplen Sklerose mit Glatiramer-Azetat

  2002cites this paper
• Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years.

  2002cites this paper
• Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS

  2001cites this paper
• Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses.

  2001cites this paper
• Glatiramer acetate in the treatment of multiple sclerosis

  2001cites this paper
• Multiple sclerosis treatment 2001.

  2001cites this paper
• Glatiramer acetate blocks interleukin-1-dependent nuclear factor-kappaB activation and RANTES expression in human U-251 MG astroglial cells.

  2001cites this paper
• Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis

  2001cites this paper
• [Therapeutic indications targeting etiology. (With the exception of primary progressive forms)].

  2001cites this paper
• Mechanisms of action of glatiramer acetate in multiple sclerosis

  2001cites this paper
• Meta-Analysis of Clinical Trials with Copolymer 1 in Multiple Sclerosis

  2000cites this paper
• Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.

  2000cites this paper
• Immunization with the C-terminal region of Trypanosoma cruzi ribosomal P1 and P2 proteins induces long-term duration cross-reactive antibodies with heart functional and structural alterations in young and aged mice.

  2000cites this paper
• Advances in Neurologic Treatments

  2000cites this paper
• Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses.

  2000cites this paper
• Copolymer 1 inhibits experimental autoimmune uveoretinitis.

  2000cites this paper
• Mechanisms of immunomodulation by glatiramer acetate

  2000cites this paper
• Autoimmunity Against Platelets in Schizophrenia

  1999cites this paper
• Arthritis-Associated HLA-DR Molecules Sclerosis- and Rheumatoid Binding Motifs of Copolymer 1 to Multiple

  1999cites this paper
• Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules.

  1999cites this paper
• Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones.

  1998cites this paper
• Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1.

  1998cites this paper
• Copolymer 1

  1997cites this paper
• Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells.

  1997cites this paper
• Cop 1 as a candidate drug for multiple sclerosis.

  1997cites this paper
• Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules

  1997cites this paper
• New insights into the mechanism of action of copolymer 1 of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis

  1996cites this paper
• Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses.

  1996cites this paper
• Newer Versus Older Treatments for Relapsing-Remitting Multiple Sclerosis

  1996cites this paper
• Clinical Trials Report: Central & Peripheral Nervous Systems: Drugs in development for the treatment of multiple sclerosis: antigen-specific therapies

  1996cites this paper
• New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.

  1996cites this paper